US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030026782A1
(en)
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
WO2001083503A2
(en)
*
|
2000-05-01 |
2001-11-08 |
Hybridon, Inc. |
MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
|
US20060142202A1
(en)
*
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US7105495B2
(en)
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
US7176296B2
(en)
|
2001-04-30 |
2007-02-13 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
PT1404873E
(pt)
|
2001-06-21 |
2013-07-30 |
Dynavax Tech Corp |
Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos
|
AU2002326561B2
(en)
*
|
2001-08-07 |
2008-04-03 |
Dynavax Technologies Corporation |
Immunomodulatory compositions, formulations, and methods for use thereof
|
US7276489B2
(en)
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
ES2318615T3
(es)
*
|
2001-11-16 |
2009-05-01 |
Coley Pharmaceutical Group, Inc. |
N-(4-(4-amino-2-etil-1h-imidazo(4,5-c)quinolin-1-il)butil)metanosulfonamida, una composicion farmaceutica que la comprende y uso de la misma.
|
WO2004080430A2
(en)
*
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Methods of improving skin quality
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
CA2474709A1
(en)
|
2002-02-04 |
2003-08-14 |
Biomira, Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
SI1478327T1
(sl)
*
|
2002-02-22 |
2015-08-31 |
Meda Ab |
Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
DE60335010D1
(de)
|
2002-08-15 |
2010-12-30 |
3M Innovative Properties Co |
Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
|
AR040996A1
(es)
*
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
US7956043B2
(en)
|
2002-12-11 |
2011-06-07 |
Coley Pharmaceutical Group, Inc. |
5′ CpG nucleic acids and methods of use
|
WO2004053452A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
DE60329223D1
(de)
|
2002-12-23 |
2009-10-22 |
Dynavax Tech Corp |
Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung
|
WO2004060319A2
(en)
|
2002-12-30 |
2004-07-22 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
MXPA05007652A
(es)
|
2003-01-16 |
2006-02-22 |
Hybridon Inc |
Modulacion de propiedades inmunoestimulantes de compuestos basados en oligonucleotido mediante la utilizacion de dinucleotidos inmunoestimulantes modificados.
|
US7354907B2
(en)
*
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
WO2004071459A2
(en)
*
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor 8
|
ES2385933T3
(es)
|
2003-02-20 |
2012-08-03 |
University Of Connecticut Health Center |
Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina.
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
KR100681470B1
(ko)
*
|
2003-03-03 |
2007-02-12 |
연세대학교 산학협력단 |
면역반응 증진용 올리고뉴크레오타이드
|
US8110582B2
(en)
|
2003-03-04 |
2012-02-07 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
AU2004220465A1
(en)
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
EP1617871A4
(en)
*
|
2003-04-10 |
2010-10-06 |
3M Innovative Properties Co |
DISTRIBUTION OF IMMUNE-RESPONSE-MODIFYING COMPOUNDS USING PARTICULATE CARRIER MATERIALS CONTAINING METAL
|
JP2006528697A
(ja)
|
2003-05-16 |
2006-12-21 |
イデラ ファーマシューティカルズ インコーポレイテッド |
イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
|
CA2532926A1
(en)
|
2003-07-15 |
2005-02-03 |
Hybridon, Inc. |
Combined use of immunostimulatory oligonucleotides and cytokines or radiation
|
JP2007500712A
(ja)
*
|
2003-07-31 |
2007-01-18 |
スリーエム イノベイティブ プロパティズ カンパニー |
カプセル化および徐放のための組成物
|
EP1651216A2
(en)
*
|
2003-08-05 |
2006-05-03 |
3M Innovative Properties Company |
Infection prophylaxis using immune response modifier compounds
|
EP1653914A4
(en)
|
2003-08-12 |
2008-10-29 |
3M Innovative Properties Co |
COMPOUNDS CONTAINING OXIME SUBSTITUTED IMIDAZO STRUCTURE
|
CA2551075A1
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
AU2004268616B2
(en)
|
2003-08-25 |
2010-10-07 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
US7897597B2
(en)
|
2003-08-27 |
2011-03-01 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
US20060216333A1
(en)
*
|
2003-09-02 |
2006-09-28 |
Miller Richard L |
Methods related to the treatment of mucosal associated conditions
|
WO2005023190A2
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
WO2005030259A2
(en)
|
2003-09-25 |
2005-04-07 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid-lipophilic conjugates
|
BRPI0414856A
(pt)
|
2003-10-03 |
2006-11-21 |
3M Innovative Properties Co |
imidazoquinolinas alcóxi-substituìdas
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
US8188254B2
(en)
|
2003-10-30 |
2012-05-29 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
JP2007509987A
(ja)
*
|
2003-10-31 |
2007-04-19 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤化合物による好中球活性化
|
EP1682544A4
(en)
|
2003-11-14 |
2009-05-06 |
3M Innovative Properties Co |
HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
|
AU2004291101A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
BRPI0416936A
(pt)
|
2003-11-25 |
2007-01-16 |
3M Innovative Properties Co |
sistemas de anel de imidazo substituìdos e métodos
|
WO2005055932A2
(en)
*
|
2003-12-02 |
2005-06-23 |
3M Innovative Properties Company |
Therapeutic combinations and methods including irm compounds
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
US7713535B2
(en)
|
2003-12-08 |
2010-05-11 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties by small oligonucleotide-based compounds
|
US8802853B2
(en)
|
2003-12-29 |
2014-08-12 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
EP1699398A4
(en)
*
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
IMPROVING THE IMMUNE RESPONSE
|
AU2004312508A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
TW200612932A
(en)
|
2004-03-24 |
2006-05-01 |
3M Innovative Properties Co |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
CA2564855A1
(en)
*
|
2004-04-28 |
2005-10-28 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
EP3001990A1
(en)
|
2004-05-28 |
2016-04-06 |
Oryxe |
A mixture for transdermal delivery of low& and high molecular weight compounds
|
JP2008501807A
(ja)
*
|
2004-06-08 |
2008-01-24 |
コーリー ファーマシューティカル ゲーエムベーハー |
抗原ならびに免疫活性化アゴニストおよび免疫活性化アンタゴニストのための担体基本骨格としての無塩基オリゴヌクレオチド
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
US20060045886A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Kedl Ross M |
HIV immunostimulatory compositions
|
EP1804583A4
(en)
*
|
2004-10-08 |
2009-05-20 |
3M Innovative Properties Co |
ADJUVANT FOR DNA VACCINE
|
JP5313502B2
(ja)
|
2004-12-30 |
2013-10-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
WO2006074003A2
(en)
|
2004-12-30 |
2006-07-13 |
3M Innovative Properties Company |
CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
|
PL1830876T3
(pl)
*
|
2004-12-30 |
2015-09-30 |
Meda Ab |
Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
|
CA2597092A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
WO2006086634A2
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
EP1863814A1
(en)
|
2005-04-01 |
2007-12-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
US7943610B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
AU2006304205C1
(en)
*
|
2005-10-12 |
2012-11-15 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
US7776834B2
(en)
*
|
2005-11-07 |
2010-08-17 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
US7470674B2
(en)
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
EP1942945B1
(en)
|
2005-11-07 |
2011-10-19 |
Idera Pharmaceuticals |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
WO2007100634A2
(en)
*
|
2006-02-22 |
2007-09-07 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
AU2008286735A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Idera Pharmaceuticals, Inc. |
Toll like receptor modulators
|
CN102281880A
(zh)
*
|
2008-10-06 |
2011-12-14 |
艾德拉药物股份有限公司 |
类Toll受体抑制剂在高胆固醇血症和高脂血症及相关疾病的预防和治疗中的用途
|
US20110009477A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Idera Pharmaceuticals, Inc. |
Oligonucleotide-based compounds as inhibitors of toll-like receptors
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
ES2697606T3
(es)
|
2010-11-19 |
2019-01-25 |
Idera Pharmaceuticals Inc |
Compuestos de oligonucleótido inmunorregulador (IRO) para modular la respuesta inmunitaria basada en un receptor tipo Toll
|
EP3153180A1
(en)
|
2011-06-03 |
2017-04-12 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
EP2717919B1
(en)
|
2011-06-03 |
2016-08-03 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
EP3024476A1
(en)
|
2013-07-26 |
2016-06-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
US11260018B2
(en)
|
2015-09-17 |
2022-03-01 |
Jrx Biotechnology, Inc. |
Approaches for improving skin hydration and moisturization
|
EP3357507A4
(en)
*
|
2015-09-30 |
2019-05-29 |
Shionogi & Co., Ltd |
NUCLEIC ACID DERIVATIVE WITH IMMUNOSTIMULATING EFFECT
|
US10940201B2
(en)
|
2015-09-30 |
2021-03-09 |
Shionogi & Co., Ltd. |
Nucleic acid derivative having immunostimulatory activity
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
IL292658A
(en)
|
2016-09-15 |
2022-07-01 |
Idera Pharmaceuticals Inc |
Immune modulation with tlr9 agonists for cancer therapy
|
JP6611298B2
(ja)
*
|
2017-03-29 |
2019-11-27 |
塩野義製薬株式会社 |
免疫賦活活性を有する核酸誘導体
|
MX2020008455A
(es)
|
2018-02-28 |
2021-10-26 |
Pfizer |
Variantes de il-15 y usos de las mismas.
|
SG11202010934SA
(en)
|
2018-05-23 |
2020-12-30 |
Pfizer |
Antibodies specific for gucy2c and uses thereof
|
KR102602329B1
(ko)
|
2018-05-23 |
2023-11-16 |
화이자 인코포레이티드 |
Cd3에 특이적인 항체 및 이의 용도
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
BR112023000701A2
(pt)
|
2020-07-17 |
2023-02-07 |
Pfizer |
Anticorpos terapêuticos e usos dos mesmos
|